Ranked #2,073 of 8,699 institutional investors
Commodore Capital LP
New York, NY
$1.22B
US stock portfolio at live prices · today −$3.3M (−0.27%)
Market closed. Prices as of Nov 20, 6:11 AM ET
- Value at quarter end (Q3 2026)
- $1.29B
- Change from Q2 2026
- −$388.3M (−23.13%)
- Positions
- 27 · 6 new, 4 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$258M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesRLAY 15.7%ELVN 12.5%ANRO 5.93%SYRE 5.61%AMLX 4.30%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| RLAY Relay Therapeutics, Inc. | 12,000,000 | $191M | 15.7% | Unchanged |
| ELVN Enliven Therapeutics, Inc. | 3,275,000 | $152M | 12.5% | Unchanged |
| ANRO Alto Neuroscience Inc | 2,723,196 | $72.2M | 5.93% | Unchanged |
| SYRE Spyre Therapeutics, Inc. | 700,000 | $68.3M | 5.61% | Reduced −17% |
| AMLX Amylyx Pharmaceuticals, Inc. | 2,000,000 | $52.4M | 4.30% | Reduced −65% |
| LBRX LB Pharmaceuticals Inc | 1,282,273 | $51.3M | 4.22% | Reduced −15% |
| COGT Cogent Biosciences, Inc. | 1,265,000 | $35.1M | 2.88% | Reduced −59% |
| TYRA Tyra Biosciences, Inc. | 1,725,000 | $34.0M | 2.80% | Reduced −8% |
| KRSA Korsana Biosciences, Inc. | 877,022 | $31.1M | 2.55% | New |
| CLDX Celldex Therapeutics, Inc. | 1,000,000 | $28.0M | 2.30% | Reduced −26% |
| SRZN Surrozen, Inc. | 885,000 | $27.1M | 2.23% | New |
| SGMT Sagimet Biosciences Inc. | 2,757,742 | $26.5M | 2.18% | New |
| KYMR Kymera Therapeutics, Inc. | 175,000 | $20.9M | 1.72% | Reduced −30% |
| DFTX Definium Therapeutics, Inc. | 700,000 | $20.6M | 1.70% | Reduced −65% |
| ATTO Attovia Therapeutics, Inc. | 1,160,000 | $18.1M | 1.48% | New |
| ADRX ADARx Pharmaceuticals, Inc. | 1,260,577 | $17.8M | 1.47% | New |
| PEPG PepGen Inc. | 4,475,000 | $17.6M | 1.44% | Unchanged |
| ANTX AN2 Therapeutics, Inc. | 2,933,680 | $15.3M | 1.26% | Unchanged |
| EDIT Editas Medicine, Inc. | 8,889,000 | $15.2M | 1.25% | Unchanged |
| AGEN Agenus Inc. | 1,985,387 | $12.2M | 1.00% | New |
| IPSC Century Therapeutics, Inc. | 8,695,652 | $11.5M | 0.94% | Unchanged |
| ASMB Assembly Biosciences, Inc. | 461,922 | $10.4M | 0.85% | Reduced −67% |
| SABS SAB Biotherapeutics, Inc. | 2,870,000 | $8.4M | 0.69% | Unchanged |
| RLMD Relmada Therapeutics, Inc. | 2,350,000 | $7.3M | 0.60% | Added +65% |
| IKT Inhibikase Therapeutics, Inc. | 5,397,488 | $7.0M | 0.58% | Unchanged |
| AVTX Avalo Therapeutics, Inc. | 1,018,319 | $6.9M | 0.56% | Unchanged |
| LONA LeonaBio, Inc. | 464,398 | $1.1M | <0.1% | Unchanged |